Level of health of the vaccine market—Global
Level of health of the vaccine market—Global
Vaccine | 2019/2020 |
---|
Bacille Calmette-Guerin (BCG) | Unhealthy1 |
Human papillomavirus (HPV) | Unhealthy |
Pneumococcal conjugate vaccine (PCV) | Concerning2 |
Pneumococcal polysaccharide | Concerning2 |
Measles | Concerning3 |
Measles-rubella | Concerning3 |
Measles-mumps-rubella (MMR) | Concerning3 |
Penta (whole-cell pertussis-containing) | Healthy4 |
Hexa (acellular pertussis-containing) | Unhealthy4 |
Tetanus-diphtheria | Healthy4 |
Inactivated polio vaccine, stand-alone | Healthy5 |
Rotavirus | Healthy6 |
1) No market study update in 2020 - same as 2019.
2) Unavailable as MI4A pneumococcal market study not yet completed.
3) Unavailable as MI4A measles market study not yet completed.
4) No market study update - same as 2019.
5) Same as 2019.
6) Unavailable as UNICEF SD market note not yet completed.
Immunization Agenda 2030 Scorecard
© Immunization Agenda 2030
Vaccine | 2019/2020 |
---|
Bacille Calmette-Guerin (BCG) | Unhealthy1 |
Human papillomavirus (HPV) | Unhealthy |
Pneumococcal conjugate vaccine (PCV) | Concerning2 |
Pneumococcal polysaccharide | Concerning2 |
Measles | Concerning3 |
Measles-rubella | Concerning3 |
Measles-mumps-rubella (MMR) | Concerning3 |
Penta (whole-cell pertussis-containing) | Healthy4 |
Hexa (acellular pertussis-containing) | Unhealthy4 |
Tetanus-diphtheria | Healthy4 |
Inactivated polio vaccine, stand-alone | Healthy5 |
Rotavirus | Healthy6 |
1) No market study update in 2020 - same as 2019.
2) Unavailable as MI4A pneumococcal market study not yet completed.
3) Unavailable as MI4A measles market study not yet completed.
4) No market study update - same as 2019.
5) Same as 2019.
6) Unavailable as UNICEF SD market note not yet completed.
Definition:
Level of health of the market, disaggregated by antigen and country typology (Gavi, non-Gavi middle-income countries, high-income countries).
Measurement approach: A number of criteria have been defined to determine the level of health of a market. The number of criteria 'met' directly determines the health of the market for each vaccine. The overall health of a vaccine market includes an assessment of the total number of suppliers, relative concentration among them, ability to distribute globally and the state of the development pipeline. The total numbers of suppliers making a specific vaccine give only a partial picture; the market share of the two largest producers provides a sense of how balanced the market is between different suppliers while reach indicates how many vaccines are truly available globally. Lastly, the "innovation" heading indicates the number of vaccines in late-stage development. Markets with a small number of current global producers but with multiple products in the pipeline are viewed as healthier than those with fewer products in the pipeline.
Calculation: Based on assessments of individual antigens and a holistic overview of each market's programmatic context, a semi-quantitative review of the individual market health will be conducted by partners such as WHO, UNICEF, Gavi, and the Bill & Melinda Gates Foundation.